Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Simcere to Commercialize Lynk's JAK1 Inhibitor in China

publication date: Mar 18, 2022

Simcere, a Nanjing biopharma, acquired China commercialization rights to a selective JAK1 inhibitor from Lynk Pharma of Hangzhou. Simcere will market LNK01001 to patients with rheumatoid arthritis and ankylosing spondylitis. Lynk will continue to be responsible for clinical development of the candidate, while Simcere will make unspecified payments to acquire the rights. Earlier this year, Lynk started a double-blind, placebo-controlled China Phase II trial of LNK01001 for ankylosing spondylitis. In head-to-head clinical studies, JAK1 inhibitors have shown advantages over existing rheumatoid arthritis treatments, according to Lynk. More details....

Stock Symbol: (HK: 2096)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China